AstraZeneca PLC has reported that their anselamimab treatment for AL amyloidosis did not meet the main trial goal as of July 16, 2025, but showed promising results in a specific patient subgroup. The study involved 406 patients globally and aims to address organ damage caused by amyloid deposits.